OrbiMed’s Zai Lab ZLAB Stock Holding History

OrbiMed’s Portfolio ZLAB Stock Details ZLAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-231,000	Closed	-$8.08M	–	126
2025 Q2	$8.08M	Buy	+231,000	New	+$7.59M	0.2%	65
2020 Q2	–	Sell	-254,000	Closed	-$13.1M	–	159
2020 Q1	$13.1M	Sell	254,000 -260,000	-51%	-$13.6M	0.22%	81
2019 Q4	$21.4M	Hold	514,000	–	–	0.31%	64
2019 Q3	$16.6M	Sell	514,000 -655,000	-56%	-$22.5M	0.32%	69
2019 Q2	$40.8M	Sell	1,169,000 -232,318	-17%	-$6.84M	0.63%	45
2019 Q1	$41.4M	Sell	1,401,318 -352,220	-20%	-$9.64M	0.64%	45
2018 Q4	$40.7M	Hold	1,753,538	–	–	0.75%	43
2018 Q3	$34.2M	Buy	1,753,538 +142,538	+9%	+$3.09M	0.41%	66
2018 Q2	$37.5M	Buy	1,611,000 +952,840	+145%	+$20.5M	0.45%	59
2018 Q1	$14.1M	Hold	658,160	–	–	0.17%	94
2017 Q4	$14M	Hold	658,160	–	–	0.18%	91
2017 Q3	$17.8M	Buy	+658,160	New	+$18.4M	0.17%	87

Other funds holding ZLAB

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed's ZLAB Position: Q3 2025 in Review

OrbiMed sold out of Zai Lab (ZLAB) in Q3 2025, closing a stake of 231,000 shares — an estimated $8.08M sold.

OrbiMed first reported a position in ZLAB in Q3 2017 and held it in 12 quarters. The position peaked at $41.4M in Q1 2019. 138 funds tracked by Wall St. Rank hold ZLAB as of Q3 2025.

OrbiMed reported no remaining Zai Lab position as of Q3 2025 after selling out during the quarter.
OrbiMed sold 231,000 Zai Lab shares in Q3 2025, an estimated $8.08M.
OrbiMed first reported a position in Zai Lab in Q3 2017 and held it in 12 quarters.
OrbiMed's Zai Lab position peaked at $41.4M in Q1 2019.
138 funds tracked by Wall St. Rank held Zai Lab as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.